
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
IND Submitted for CYT-500
Cytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer.
PRINCETON, New JerseyCytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer. CYT-500 targets prostate-specific membrane antigen (PSMA), which is abundantly expressed on the surface of prostate cancer cells. The agent incorporates the same monoclonal antibody used in Cytogen's ProstaScint (capromab pendetide) molecular imaging agent but is linked to a therapeutic payload.
Articles in this issue
over 19 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentover 19 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaover 19 years ago
New Imaging, ChemoRT Recommendations From NCCNover 19 years ago
Panitumumab Improves PFS in Advanced Colon Caover 19 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsover 19 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerover 19 years ago
FDA Approves New Every-3-Week Dosing for Aranespover 19 years ago
Telephone Often Delivers News of Breast Cancer DiagnosisNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.